Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Toxicological Sciences

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2131/JTS.39.237PMID 24646704
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.

  2013cited by this paper
• A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

  2010cited by this paper
• A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

  2010cited by this paper
• Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

  2010cited by this paper
• Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

  2010cited by this paper
• Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors

  2010cited by this paper
• Effect of the Multitargeted Receptor Tyrosine Kinase Inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on Blood Pressure in Conscious Rats and Mice: Reversal with Antihypertensive Agents and Effect on Tumor Growth Inhibition

  2009cited by this paper
• Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

  2009cited by this paper
• Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

  2009cited by this paper
• Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

  2009cited by this paper
• Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

  2009cited by this paper
• Adverse effects of anticancer agents that target the VEGF pathway

  2009cited by this paper
• Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

  2008cited by this paper
• Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

  2008cited by this paper
• A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

  2008cited by this paper
• Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.

  2008cited by this paper
• Home blood-pressure monitoring in patients receiving sunitinib.

  2008cited by this paper
• Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

  2007cited by this paper
• Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)

  2007cited by this paper
• Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

  2007cited by this paper
• Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

  2007cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

  2005cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

  1997cited by this paper
• Learning Objectives

  1990cited by this paper

• Non-clinical cardiovascular safety testing: Current status, gaps and emerging trends.

  2025cites this paper
• The hypertensive effect of sorafenib is abolished by sildenafil

  2020cites this paper
• Long‐term cardiovascular effects of vandetanib and pazopanib in normotensive rats

  2019cites this paper
• Quantifying the relationship between inhibition of VEGF receptor 2, drug‐induced blood pressure elevation and hypertension

  2018cites this paper
• Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats

  2016influential citation
• Effects of acute and chronic sunitinib treatment on cardiac function and calcium/calmodulin‐dependent protein kinase II

  2015cites this paper
• Haemodynamic Assessment in Safety Pharmacology.

  2015cites this paper
• The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

  2014cites this paper
• Small Molecule Therapeutics The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH 5183284 / Debio 1347 , a Novel Selective FGFR Inhibitor

  2014cites this paper